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VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 6 9 6 – 6 9 7 697Authors’ Response to ‘‘Comparative Effectiveness and Personalized
Medicine’’ by Dr. J.C. HornbergerTo the Editor - We thank Dr. Hornberger for his interest in our recent
article, ‘‘Cost-Effectiveness of Using a Molecular Diagnostic Test to
Improve Preoperative Diagnosis of Thyroid Cancer.’’ Dr. Hornberger
raises an interesting question about the target population in our
analysis:
The sensitivity and specificity used in Najafzadeh et al.’s cost-
effectiveness analysis presumably are based on studies of
patients who have undergone surgical resection [4]. The test’s
accuracy therefore is known for the population of patients
with indeterminate pathology by FNAB who have undergone
surgical resection, but is not directly known for the population
of patients who do not undergo resection.
In response, we would like to clarify that sensitivity and
specificity are not exogenous variables in our model and, in fact,
have been estimated in this simulation. In our patient-level simula-
tion model, we generated a cohort of hypothetical patients with
indeterminate cytology. Each patient then was flagged to have either
malignant or benign nodule at the baseline by mimicking malig-
nancy rates across different diagnostic categories that have been
reported in the literature (please see Table 1: Model Assumptions
about Cytology Results) [1]. Themodel then simulated pathways that
each patient would experience if The Bethesda System for Reporting
Thyroid Cytopathology (TBSRTC) guidelines with and without the
molecular diagnostic (DX) test had been followed. Consequently, by
knowing patients’ actual tumor status at the baseline (disease) and
whether they were referred for a surgery or not at the end of
simulation (overall test result), we were able to estimate sensitivity
and specificity of each diagnostic strategy. Please note that diagnos-
tic characteristics (e.g., sensitivity and specificity) have been reported
as model outcomes in Table 4 and not in Tables 1, 2, or 3, in which
we have reported model assumptions. We would like to emphasize
that in our model the probability of malignancy conditional on being
classified as benign in fine-needle aspiration biopsy (FNAB) cytology
is not zero. Therefore, patients with benign cytology who did not
undergo surgery could still develop cancer in our simulation (Cibas
and Ali report that up to 3% of patients with benign cytology might
have malignant tumors) [2].Overall, we believe that the results of our analysis are applic-
able to all patients with indeterminate cytology and not exclu-
sively to those who have been referred for a surgical procedure.
Nevertheless, we agree with Dr. Hornberger that more accurate
information about prognosis of patients who are not referred to
surgical procedures will be very useful. As has been correctly
mentioned, obtaining pathological diagnosis in this group
involves some ethical hurdles. Nevertheless, we believe that
long-term observational studies might be a practical tool to
tackle this problem.
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